KKR to buy medical device maker Integer for $5.7B
What's the deal? KKR has agreed to acquire Integer Holdings CorporationDealroom has a profile for this one. Try Dealroom → in an all-cash transaction valued at an enterprise value of approximately $5.7 billion. Integer stockholders will receive $127 per share, a 51.8% premium to the company's closing price on April 29, 2026, the day before it announced a strategic review. An affiliate of KKR-managed funds will buy all outstanding shares.
What each side brings: Integer, based in Plano, Texas, is a global medical device contract development and manufacturing organisation (CDMO) with 11,000 associates. KKR is a global investment firm with a portfolio spanning healthcare.
Why now? The deal follows a board-led strategic review that Integer announced on April 30, 2026. In consultation with advisers, the board weighed a range of alternatives and concluded the KKR offer delivered "immediate and certain value" to stockholders.
What's the endgame? As a KKR portfolio company, Integer gains long-term capital to invest in capacity, technology, and talent. KKR also plans a broad-based employee ownership program after closing, extending a model it has applied across more than 90 portfolio companies since 2011.
What could go wrong? The transaction is expected to close by the end of the year, but remains subject to customary conditions, including approval by Integer stockholders and regulatory clearance.
The signal: Private capital continues to circle medical device manufacturing, where durable end-markets and outsourced production draw long-term investors. "Integer is an exceptional platform with highly differentiated capabilities across a global manufacturing footprint," said Max Lin, a partner at KKR. Taking the company private gives KKR room to fund growth away from public-market pressure.
Read more: bizwireexpress.com
Image credit: Generated with Gemini
